Martin David Harp

SeeLuma is a “Fully Digital Surgical Visualization Platform” to assist ophthalmic surgeons.

Esen Akpek, MD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss ocular surface disease and the lifestyle choices that could affect eye health. As well as what The Tear Film & Ocular Surface Society is doing to promote research on the topic.

Patients and employees, past and present, have had personal and protected health information acquired without authorization.

Dirty equipment and sterilization issues are among the many violations found by the FDA.

The month will serve to educate the public on a variety of women’s vision issues.

Brimonidine Tartrate Ophthalmic Solution is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma.

GAL-101 is a Phase 2/3-ready small molecule used to treat ophthalmic indications with high unmet medical need.

The various aspects of home monitoring for patients with age-related macular degeneration are discussed in this point/counterpoint by Prof. Rufino Silva, University of Coimbra / Coimbra Hospital and University Centre, Portugal, and Univ.-Prof. Dr. med. Robert P. Finger, PhD, Department of Ophthalmology, University of Bonn, Germany, during the 14th annual Congress on Controversies in Ophthalmology in Lisbon, Portugal

Pedro Fonseca, MD, Coimbra Hospital and University Centre, Portugal, and Andrew G. Lee, MD, Blanton Eye Institute, Houston Methodist, Texas, USA, discuss the various pros and cons of offering teprotumumab for all patients with thyroid eye disease.

There have been 8 reported patients with vision loss as well as 4 reports of enucleation, or surgical removal of eyeball.

Avenova Eye Health Support oral supplement aims to comfort dry eyes and support overall eye health.

The month will help to bring awareness to eye safety in the workplace and keep eyes safe and protected on the job.

The voluntary recall is being issued out of an “abundance of caution” due to cracks that have developed in some of the units caps of the bottles.

The event will bring together patients, care partners, allied personnel, and medical professionals to speak directly with their elected officials to discuss a variety of vision and eye health issues

Primary vitreoretinal lymphoma is a rare, aggressive, and potentially fatal retinal cancer that is diagnosed in approximately 300 to 600 patients in the United States per year.

The company is anticipating the first patient-first visit in Q1 2023 and is looking to release top-line data from the Phase 2 trial in Q4 2023.

The Alteogen Inc. subsidiary company provided an update on its ALT-L9 biosimilar to compete with EYLEA

SBI-100 Ophthalmic Emulsion is a synthetic cannabinoid derivative to treat glaucoma and ocular hypertension.

Data shows the Notal Vision Home OCT device can be used to manage wet age-related macular degeneration (AMD).

Multiple attendees of this year's EnVision Summit share insights into what makes the EnVision Summit an enjoyable experience and a great place to learn.

Multiple attendees of this year's EnVision Summit share insights into their presentations.

According to the company, reproxalap is a small-molecule modulator of reactive aldehyde species that will be used for the treatment of the signs and symptoms of dry eye disease.

Adrienne Graves, PhD, and Andrew Iwach, MD, co-founders of Glaucoma 360, share insights into the formation of the Glaucoma Research Foundation and what makes Glaucoma 360 such a unique conference.

Oluwatosin U. Smith, MD, provides some key takeaways from her Glaucoma 360 2023 presentation, "Glaucoma Management Lessons Learned from a Pandemic."

Bausch + Lomb and Modulight announce the photodynamic laser for use with photodynamic therapy was approved by the FDA for the treatment of patients with subfoveal choroidal neovascularization due to AMD.

HG004 aims to be more effective than other AAV2 products in treatment of inherited retinal diseases caused by mutations in the RPE65 gene.

Vial will be supporting RecensMedical with the phase 3 clinical trial for its Ocu-Cool system.

The Phase 2 clinical trial will evaluate darovasertib as monotherapy in neo-adjuvant and adjuvant settings in primary, non-metastatic uveal melanoma (UM) patients.

The intent of the award is to recognize early-career researchers who have exhibited excellence in research, as well as their fundamental scientific discoveries, concepts and novel technologies which have led to, or have the promise of leading to, clinical application.

After comparing two techniques of corneal transplant tissue preparation, research shows a newer, faster technique is safe and effective.